Crizotinib, a first generation ALK TKI, has been approved by the FDA for treating locally advanced or metastatic ALK-positive NSCLC tumors by competitively binding to the ATP-binding site [25]. This evidence concerns the gene ALK and non-small cell lung carcinoma.